Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 24Wilms Tumor 9Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Glioma 7Rhabdoid Tumor 6Osteosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma 5Rhabdomyosarcoma 5Central Nervous System Neoplasms 5Sarcoma, Ewing 4Lung Neoplasms 4Carcinoma, Renal Cell 4Melanoma 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Lymphoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Nivolumab 3Specimen Handling 2trifluridine tipiracil drug combination 1entinostat 1X-Rays 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Fluorouracil 1Fentanyl 1CTLA-4 Antigen 1Bone Density 1Bevacizumab 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Desmoid Tumors × X-Rays × Genitourinary × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡